Cosmos Health Guides Q4 U.S. Revenue to $15M at 70% Gross Margin as Subscriptions Jump 42% in Five Days
COSM has more than doubled off its 52-week low of $0.162.
Summary
Cosmos Health issued a Q4 2026 U.S. outlook of roughly $15M revenue and $10.5M gross profit at a ~70% margin, with subscriptions expected to supply more than three-quarters of that revenue. The company says active U.S. subscriptions rose 42% to 8,940 in just five days, monthly subscription value climbed 44% to $1.33M, and checkout orders reached 14,624, up 34%. Management expects daily U.S. sales to more than triple from $60,000 at the start of the quarter to over $200,000 by year-end, with more than 40,000 subscriptions. The numbers are preliminary, unaudited platform metrics and the guidance rests on internal assumptions, so the credibility gap matters: this follows the October 9 8-K with preliminary Q3 revenue of $17.4M and a Q2 that showed a doubled net loss and going concern doubt. The stock trades near $0.33 with a small market cap, so a U.S. direct-to-consumer ramp at 70% margins would be a meaningful swing factor if it materializes.
At the time of this announcement, COSM was trading at $0.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $33.2M. The 52-week trading range was $0.16 to $1.14. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.